- VernacularTitle:Molecular diagnosis and treatment of meningiomas: an expert consensus (2022)
- Author:
Jiaojiao DENG
1
;
Lingyang HUA
2
;
Liuguan BIAN
3
;
Hong CHEN
4
;
Ligang CHEN
5
;
Hongwei CHENG
6
;
Changwu DOU
7
;
Dangmurenjiapu GENG
8
;
Tao HONG
9
;
Hongming JI
10
;
Yugang JIANG
11
;
Qing LAN
12
;
Gang LI
13
;
Zhixiong LIU
14
;
Songtao QI
15
;
Yan QU
16
;
Songsheng SHI
17
;
Xiaochuan SUN
18
;
Haijun WANG
19
;
Yongping YOU
20
;
Hualin YU
21
;
Shuyuan YUE
22
;
Jianming ZHANG
23
;
Xiaohua ZHANG
24
;
Shuo WANG
25
;
Ying MAO
1
;
Ping ZHONG
2
;
Ye GONG
1
Author Information
- Collective Name:Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association
- Publication Type:Journal Article
- MeSH: Humans; Meningioma/pathology*; Consensus; Neurosurgical Procedures; Meningeal Neoplasms/pathology*
- From: Chinese Medical Journal 2022;135(16):1894-1912
- CountryChina
- Language:English
-
Abstract:
ABSTRACT:Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of molecular diagnostics in meningiomas. To follow the revision of WHO CNS5, this expert consensus statement was formed jointly by the Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association together with neuropathologists and evidence-based experts. The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients.
REGISTRATION:Practice guideline REgistration for transPAREncy (PREPARE), IPGRP-2022CN234.